Str (94fb4253 7822 4043 8ef9 0f8d93642feb 01)
Donepezil Hydrochloride
Product Images NDC 68151-3114
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68151-3114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig.1 (94fb4253 7822 4043 8ef9 0f8d93642feb 02)
The text provides a table showing the mean change in ADAS-cog score from baseline to 6, 12, and 18 weeks of drug treatment with Donepezil Hydrochloride Tablets at 5mg and 10mg, versus placebo. There is also reference to "Clinical Improvement" and "Clinical Decline". No further information is available.*
Figure 2 (94fb4253 7822 4043 8ef9 0f8d93642feb 03)
This is a graph displaying the cumulative percentage of patients receiving Donepezil Hydrochloride Tablets at different dosages and also the placebo, based on their change in ADAS-cog score. The ADAS-cog score is a measure of cognitive function in Alzheimer's disease patients. The graph shows that patients receiving the higher dose of Donepezil Hydrochloride Tablets (10 mg/day) experienced greater improvement in cognitive function compared to those receiving a lower dose (5 mg/day) or placebo. The x-axis shows the change from baseline (initial ADAS-cog score) and the y-axis shows the cumulative percentage of patients.*
Figure 3 (94fb4253 7822 4043 8ef9 0f8d93642feb 04)
Not available.*
5 (94fb4253 7822 4043 8ef9 0f8d93642feb 05)
This is a graph that shows the change from baseline in ADAS-cog (a test for assessing cognitive function in patients with Alzheimer's disease) over 12 weeks of drug treatment with either Donepezil Hydrochloride Tablets or a Placebo. The y-axis represents the mean (+SE) change in ADAS-cog score, while the x-axis represents the treatment period in weeks. The graph shows that both dosages of Donepezil Hydrochloride Tablets resulted in clinical improvement over the 12 weeks, while the Placebo group experienced clinical decline in cognitive function.*
Figure 5 (94fb4253 7822 4043 8ef9 0f8d93642feb 06)
Figure 6 (94fb4253 7822 4043 8ef9 0f8d93642feb 07)
Figure 7 (94fb4253 7822 4043 8ef9 0f8d93642feb 08)
Figure 8 (94fb4253 7822 4043 8ef9 0f8d93642feb 09)
The text provides a graph showing the cumulative percentage of patients and the SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride Tablets 10mg/day and Placebo. The graph shows that Donepezil Hydrochloride Tablets have a positive effect compared to a Placebo in improving SIB scores.*
Figure 9 (94fb4253 7822 4043 8ef9 0f8d93642feb 10)
This is a graph that shows the time course of change from baseline in ADCS-ADL-Severe score for patients who completed 6 months of treatment. The x-axis represents the time in months, while the y-axis represents the ADCS-ADL-Severe score. There are two lines: one for patients who received donepezil hydrochloride tablets 10 mg/day and one for patients who received a placebo. The graph suggests that patients who received donepezil hydrochloride tablets experienced some clinical improvement. However, a detailed description of the results cannot be given due to lack of context.*
Figure 10 (94fb4253 7822 4043 8ef9 0f8d93642feb 11)
This appears to be a graph with the title "Cumulative Percentage of Patients" with a Y-axis starting at 0 and ending at 100. The X-axis has a scale from 0-100 with marks at 15, 10, 5, 0, -5, and -10. The graph itself has two lines - one labeled "Donepezil Hydrochloride Tablets 10 mg/day" and the other labeled "Placebo" - both running from around 20% at the left side of the graph to 100% at the right side. Below the graph is a label reading "ADCS-ADL Change from Baseline".*
Logo (94fb4253 7822 4043 8ef9 0f8d93642feb 12)
Logo (94fb4253 7822 4043 8ef9 0f8d93642feb 13)
Label Image (Lbl681513114)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
